Welcome to South West Healthcare
Leaders in healthcare, partners in wellbeing.
Please use this identifier to cite or link to this item:
https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/3629| Journal Title: | Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer |
| Authors: | Loft, Matthew Lok, Sheau Wen De Boer, Richard Malik, Laeeq Greenberg, Sally Yeo, Belinda Anton, Angelyn Nottage, Michelle Wong, Vanessa Nott, Louise Torres, Javier Barnett, Frances Lombard, Janine M. Gibbs, Peter Gately, Lucy Collins, Ian M. |
| SWH Author: | Collins, Ian M. |
| Keywords: | Breast Neoplasms Chemotherapy Breast Cancer |
| Issue Date: | Jan-2023 |
| Date Accessioned: | 2023-03-29T23:55:22Z |
| Date Available: | 2023-03-29T23:55:22Z |
| Url: | https://doi.org/10.1007/s10549-022-06856-1 |
| Format Startpage: | 67 |
| Source Volume: | 198 |
| Issue Number: | 1 |
| DOI: | 10.1007/s10549-022-06856-1 |
| Date: | 2023 2023/02/01 |
| Abstract: | Dual anti-HER2 targeted therapy and chemotherapy is the current first-line standard of care for HER2 + metastatic breast cancer (MBC), with endocrine therapy (ET) the backbone of treatment in hormone receptor positive (HR +) disease. The potential ET benefit in HER2 + /HR + patients is unknown as pivotal dual anti-HER2 clinical trials precluded ET use. |
| URI: | https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/3629 |
| Journal Title: | Breast Cancer Research and Treatment |
| Type: | Journal Article |
| Appears in Collections: | SWH Staff Publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.